In the RAMP 201 study, treatment with the combination of avutometinib and defactinib resulted in an objective response rate (ORR) of 45% (13/29) and tumor shrinkage in 86% (25/29) of evaluable patients.
the reverse stock split will become effective at 5:00 p.m. Eastern Time on May 31, 2023 (the "Effective Time") and the Company expects that its common stock will open for trading on June 1, 2023 on the Nasdaq Capital Market on a split-adjusted basis under the Company’s existing trading symbol "VSTM".
New drug combination offers ovarian cancer breakthrough
...The revolutionary treatment has been shown to significantly shrink tumours in almost half of patients with the disease
...The new treatment blocks tumour growth, helping keep the disease at bay for years. Experts said the “fantastic” and “very exciting” results from clinical trials of the drug combination, presented at the world’s largest cancer conference this weekend, showed it was “far more effective” than any available option for patients.
...The phase 2 trial, led by the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, tested the drug avutometinib alone and in combination with defactinib in 29 patients.
Trial results show almost half the patients on the new drug combination – 45% – saw their tumours shrink significantly. It proved to be almost twice as effective as the next best treatment – trametinib, which has a response rate of 26%.
Das VSTM frisches Kapital braucht war absehbar. Aber warum kommt diese KE so spät? Hier hat das Management m.M.n. eine ziemlich schlechte Figur abgegeben. Der Kurs notierte lange zwischen 10 und 13$, dort hätte man das Offering mit einer deutlich geringeren Verwässerung machen können/sollen/müssen. Aktuell gibt es ca. 25 Mio. Aktien + die rund 18 Mio. (inkl. warrants) aus dem Offering ergibt eine Verwässerung von bis zu 72%.
Thread abonnieren
